# Study of a 4-phasic Oral Contraceptive for the Treatment of Heavy Menstrual Bleeding

> **NCT01638923** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 339 (actual)

## Conditions studied

- Metrorrhagia

## Interventions

- **DRUG:** EV/DNG (Qlaira, Natazia, BAY86-5027)
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01638923
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06
- **Primary completion:** 2015-06
- **Final completion:** 2015-06
- **Target enrollment:** 339 (ACTUAL)
- **Last updated:** 2015-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01638923

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01638923, "Study of a 4-phasic Oral Contraceptive for the Treatment of Heavy Menstrual Bleeding". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01638923. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*